{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Number of Gy delivered to each tumor as calculated using the MIRD dosimetry formula on PET data","groups":[{"description":"Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV","id":"OG000","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan"}],"populationDescription":"Only one patient registered. No patient data analyzed","reportingStatus":"POSTED","timeFrame":"At day 11","title":"Dosimetry Calculations of Yttrium Y 90 Ibritumomab Tiuxetan Assessed by PET/MRI","type":"SECONDARY"}